[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 6, 1995

The Postmenopausal Estrogen/Progestin Interventions Trial

Author Affiliations

University of Texas Southwestern Medical Center at Dallas

JAMA. 1995;274(21):1675-1676. doi:10.1001/jama.1995.03530210029022

To the Editor.  —I read with interest the results of the PEPI trial1 regarding the effects of estrogen/progestin regimens on plasma lipid and lipoprotein levels in postmenopausal women. The effects of therapy on plasma triglycerides, however, were not clear. Part of the reason could be the incorrect conversion of mg/dL values to mmol/L. For example, the authors state that "the laboratory exclusions included... triglyceride level of 12.93 mmol/L or more (≥500 mg/dL)," whereas it should have been 5.6 mmol/L. Therefore, it is not clear which baseline values of fasting plasma triglycerides (ie, in mmol/L or in mg/dL) in their Table 1 are correct. Further, if the mean changes in fasting plasma triglyceride concentrations during the study given in their Table 2 are correct, how could there be a 20% to 25% increase above baseline in plasma triglyceride concentrations with different regimens of estrogen and estrogen/progestin therapy as shown in their

First Page Preview View Large
First page PDF preview
First page PDF preview